TGA warning for top drug class

The TGA has followed in the footsteps of its overseas counterparts and added intestinal obstruction, including ileus, as a potential adverse effect to the Product Information (PI) of all GLP-1 receptor agonists (RAs) available in Australia.

Drugs impacted include Eli Lilly's Trulicty and Mounjaro, Novo Nordisk's semaglutide franchise, Ozempic, Wegovy, and Rybelsus along with its liraglutide-containing meds Saxenda, Victoza, and Xultophy.

AstraZeneca's Byetta, which was discontinued in Australia in 2022 already had the warning in its PI.